Top Page
CSPC Pharmaceutical Group
(OTC:1093)
CSPC Pharmaceutical Group (1093) vs. iShares MSCI Hong Kong ETF (EWH)
CSPC Pharmaceutical Group Business Overview & Revenue Model
CSPC Pharmaceutical Group Financial Statement Overview
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 30.87B | 34.60B | 31.59B | 33.59B | 28.03B |
| Gross Profit | 21.60B | 24.40B | 22.73B | 25.47B | 21.00B |
| EBITDA | 6.96B | 8.53B | 8.66B | 9.28B | 8.09B |
| Net Income | 4.61B | 5.87B | 6.09B | 5.61B | 5.16B |
Balance Sheet | |||||
| Total Assets | 44.39B | 46.28B | 41.77B | 42.50B | 35.65B |
| Cash, Cash Equivalents and Short-Term Investments | 8.60B | 13.09B | 13.68B | 13.87B | 10.47B |
| Total Debt | 507.33M | 706.90M | 659.28M | 115.04M | 375.51M |
| Total Liabilities | 10.52B | 11.26B | 11.07B | 9.37B | 8.28B |
| Stockholders Equity | 32.26B | 33.20B | 29.77B | 31.79B | 26.48B |
Cash Flow | |||||
| Free Cash Flow | 1.86B | 2.29B | 5.32B | 3.74B | 5.91B |
| Operating Cash Flow | 4.53B | 4.18B | 7.63B | 4.64B | 6.74B |
| Investing Cash Flow | -3.86B | 607.27M | -6.80B | -637.33M | -2.13B |
| Financing Cash Flow | -5.25B | -2.30B | -1.90B | -2.20B | -1.47B |
CSPC Pharmaceutical Group Technical Analysis
CSPC Pharmaceutical Group Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | $104.56B | 25.74 | 11.30% | 2.80% | -18.07% | -33.27% | |
73 Outperform | 159.64B | 35.04 | 8.03% | ― | 16.90% | 63.11% | |
68 Neutral | 142.18B | 35.89 | 10.95% | 1.13% | 13.69% | 50.71% | |
68 Neutral | 56.70B | 7.80 | 8.94% | 4.06% | -2.68% | -21.46% | |
63 Neutral | 210.96B | 40.96 | 15.24% | 1.05% | 8.68% | 0.82% | |
55 Neutral | 159.71B | 125.54 | -0.72% | ― | 52.78% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
CSPC Pharmaceutical Group Corporate Events
CSPC Innovation Pharmaceutical Co., Ltd., a subsidiary of CSPC Pharmaceutical Group, reported its unaudited financial results for the first half of 2025, revealing a 7.99% increase in operating revenue compared to the same period last year. However, the company experienced a net loss attributable to shareholders, highlighting challenges in profitability despite increased revenue. The announcement underscores the importance for stakeholders to exercise caution when dealing in the company’s securities due to the unaudited nature of the financial information.
CSPC Pharmaceutical Group Limited has announced a board meeting scheduled for August 22, 2025, to approve the unaudited interim results for the first half of the year. This meeting is significant as it will provide insights into the company’s financial performance and strategic direction, impacting stakeholders and potentially influencing its market position.
CSPC Pharmaceutical Group announced that its application for marketing approval of Semaglutide Injection, a treatment for type 2 diabetes, has been accepted by China’s National Medical Products Administration. This product, developed by its subsidiary CSPC Baike, shows significant clinical advantages in glycemic control and safety compared to existing treatments. The company is also conducting trials for its use in treating obesity, indicating a strategic expansion in its product offerings to benefit a broader patient base.
CSPC Pharmaceutical Group has entered into an exclusive license agreement with Madrigal Pharmaceuticals for the global development, manufacturing, and commercialization of its oral small molecule GLP-1 receptor agonist, SYH2086. Under this agreement, CSPC will receive up to $2.075 billion, including an upfront payment and potential milestone payments, while retaining rights to develop similar products in China. This strategic partnership is expected to enhance CSPC’s market positioning in the pharmaceutical industry, particularly in the diabetes and obesity treatment sectors.
CSPC Pharmaceutical Group Limited has announced that its Mesalazine Enteric-Coated Tablets have received drug registration approval from China’s National Medical Products Administration. This product, used for treating ulcerative colitis and Crohn’s disease, enriches the company’s offerings in immune system therapeutics and highlights its commitment to providing effective anti-inflammatory treatments.
CSPC Pharmaceutical Group has received approval from China’s National Medical Products Administration to conduct clinical trials for its high-concentration hydroxocobalamin hydrochloride injection, aimed at treating methylmalonic acidemia (MMA). This approval marks the first hydroxocobalamin injection approved in China for MMA, addressing a significant unmet medical need and potentially offering a new treatment option for patients with this rare metabolic disorder.
CSPC Pharmaceutical Group Limited has announced a change in the composition of its Nomination Committee with the appointment of Ms. LI Quan as a member, effective June 27, 2025. This strategic move is expected to enhance the company’s governance structure and potentially influence its decision-making processes, reflecting its commitment to strengthening leadership and oversight.
CSPC Pharmaceutical Group Limited has announced the composition of its board of directors, including both executive and independent non-executive directors. This announcement provides clarity on the roles and functions of the board members, which is crucial for stakeholders to understand the company’s governance structure.
CSPC Pharmaceutical Group Limited has updated the terms of reference for its Nomination Committee, which is responsible for reviewing the board’s structure and diversity, identifying and recommending director candidates, and assessing the independence of non-executive directors. This move aims to enhance the company’s governance and ensure alignment with its corporate strategy, potentially impacting its operational efficiency and stakeholder confidence.
CSPC Pharmaceutical Group Limited has announced the signing of new lease agreements as the previous ones are set to expire in June 2025. The new agreements involve several subsidiaries of the company and are structured as connected transactions under Hong Kong’s Listing Rules. These agreements, which extend the leases for various premises for three years, are subject to certain reporting and announcement requirements, reflecting the company’s ongoing operational adjustments and compliance with regulatory standards.
CSPC Pharmaceutical Group has announced that its Meloxicam Injection (Ⅲ), a nanocrystal product for intravenous administration, has received drug registration approval in China. This approval marks a significant advancement in the company’s product portfolio, enhancing its position in the analgesic treatment market and demonstrating a breakthrough in nanomedicine research.
CSPC Pharmaceutical Group has entered into a strategic research collaboration with AstraZeneca to discover and develop novel oral small molecule candidates using CSPC’s AI-driven drug discovery platform. This agreement allows AstraZeneca to potentially license these candidates for global development and commercialization, with CSPC receiving significant upfront and milestone payments, as well as potential royalties, indicating a substantial impact on CSPC’s operations and industry positioning.
CSPC Pharmaceutical Group has received approval from the U.S. FDA to conduct clinical trials for its new antibody-drug conjugate, SYS6040, targeting advanced solid tumors. This development signifies a significant step in the company’s expansion into the U.S. market, potentially enhancing its competitive position in oncology therapeutics.
CSPC Pharmaceutical Group Limited has announced that its Cobamamide Capsules have received drug registration approval from the National Medical Products Administration of China. This approval enhances the company’s product portfolio in the therapeutic areas of hematology and neurology, potentially strengthening its market position and offering new treatment options for various types of anemia and nerve-related conditions.
CSPC Pharmaceutical Group announced that its drug JMT101 has been granted Breakthrough Therapy Designation in China for treating advanced colorectal cancer. This designation, based on promising phase II clinical trial results, highlights JMT101’s potential to improve treatment outcomes for patients who have failed standard therapies, positioning it as a potential new standard for later-line colorectal cancer treatment.
CSPC Pharmaceutical Group Limited announced the successful passing of all resolutions at its Annual General Meeting held on May 30, 2025. Key resolutions included the approval of financial statements for 2024, the declaration of a final dividend, re-election of directors, and the granting of mandates for share buy-backs and issuance. These resolutions reflect the company’s strategic direction and commitment to shareholder value, potentially impacting its market positioning and stakeholder confidence.
CSPC Pharmaceutical Group has announced ongoing negotiations for three potential license and collaboration transactions aimed at the development and commercialization of its pharmaceutical products, including EGFR-ADC. These transactions could bring in approximately US$5 billion in aggregate payments, with one deal expected to be finalized by June 2025, potentially impacting the company’s market positioning and financial outlook.
CSPC Pharmaceutical Group reported a significant decline in its quarterly financial results for the three months ended March 31, 2025. The company’s total revenue decreased by 21.9% compared to the previous year, primarily due to a 27.3% drop in finished drug sales, impacted by industry policies such as centralized procurement and drug price adjustments. Despite this, the bulk products segment saw a 14.6% revenue increase, driven by higher demand and prices for vitamin C products. The company has been actively promoting product internationalization and out-licensing initiatives, which have contributed to a rise in license fee income, partially offsetting the decline in drug sales and providing potential future growth.
CSPC Pharmaceutical Group Limited has announced that its bispecific fusion protein drug, JMT106, has received approval from the National Medical Products Administration of China to conduct clinical trials for advanced solid tumors. This approval, alongside a similar approval from the U.S. FDA, highlights the drug’s potential in treating various cancers, including hepatocellular carcinoma and ovarian cancer, and signifies a promising step in the company’s clinical development efforts.
CSPC Pharmaceutical Group announced that its drug CPO301 has received the third Fast Track designation from the U.S. FDA for treating advanced non-small cell lung cancer (NSCLC) without EGFR mutations. This designation highlights the drug’s promising clinical efficacy and is expected to expedite its development and registration globally, potentially enhancing CSPC’s position in the oncology market.
CSPC Pharmaceutical Group Limited has announced a board meeting scheduled for May 29, 2025, to approve the unaudited first quarterly results for the period ending March 31, 2025. This meeting is significant as it will provide insights into the company’s financial performance for the first quarter of 2025, which could impact its market positioning and stakeholder confidence.